Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;47(4):823-33.
doi: 10.4143/crt.2014.074. Epub 2015 Jan 2.

APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer

Affiliations

APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer

Ju Hyun Shin et al. Cancer Res Treat. 2015 Oct.

Abstract

Purpose: Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer.

Materials and methods: Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1.

Results: Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548 ± 0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547 ± 0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence.

Conclusion: Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.

Keywords: Apurinic/apyrimidinic endonuclease 1/redox factor-1; Biological markers; Enzyme-linked immunosorbent assay; Urinary bladder neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1.
Fig. 1.
Serum apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) expression is elevated in bladder cancer. (A) Serum APE1/Ref-1 was assayed using an enzyme-linked immunosorbent assay. The results are presented as a scatter plot. Each dot represents one patient (n=55 for non-cancer controls, n=51 for bladder cancer). ***p < 0.01 (compared with the control group). (B) Receiver operating curves of APE1/Ref-1 in bladder cancer detection. The area under curve (AUC) for detection of all cancer by APE1/Ref-1 was 0.82.
Fig. 2.
Fig. 2.
Serum apurinic/apyrimidinic endonuclease1/redox factor-1 (APE1/Ref-1) levels are associated with bladder tumor grade, stage, muscle invasion, and recurrence. Serum APE1/Ref-1 levels were assayed using an enzyme-linked immunosorbent assay. (A) Each bar shows the mean±standard error (SE) (n=16 for grade I, n=12 for grade II, n=23 for grade III, and n=55 for non-cancer controls). *p < 0.05 vs. control, **p < 0.01 vs. control. (B) Receiver operating curves for APE1/Ref-1 detection of different bladder tumor grades. (C) Serum APE1/Ref-1 levels are elevated in patients with higher stage tumors. Each bar shows the mean±SE (n=21 for stage Ta, n=17 for stage T1, n=13 for stage T2-3, and n=55 for non-cancer controls). *p < 0.05 vs. control, **p < 0.01 vs. control. (D) Receiver operating curves for APE1/Ref-1 detection of different bladder tumor stages. (E) Serum APE1/Ref-1 levels are higher in patients with muscle invasive bladder cancer. Each bar shows the mean±SE (n=38 for nonmuscle invasive bladder cancer [NMIBC], n=13 for muscle invasive bladder cancer [MIBC], and n=55 for non-cancer controls). *p < 0.05, **p < 0.01 vs. control. (F) Receiver operating curves for APE1/Ref-1 detection of NMIBC and MIBC. (G) Serum APE1/Ref-1 levels are higher in patients with recurrent tumors. Each bar shows the mean±SE (n=31 for non-recurrence, n=20 for recurrence, and n=55 for non-cancer controls). *p < 0.05, **p < 0.01 vs. control. (H) Receiver operating curves for APE1/Ref-1 detection of recurrent bladder tumors.
Fig. 3.
Fig. 3.
Apurinic/apyrimidinic endonuclease1/redox factor-1 (APE1/Ref-1) expression is elevated in bladder cancer. (A) Representative immunoblot for APE1/Ref-1 in bladder tissues of bladder cancer patients. N, non-tumor tissue as normal tissue; T, tumor tissue. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. Each bar shows the mean±standard error (n=2 for non-tumor, n=4 for tumor tissues). *p < 0.05 vs. non-tumor regions. (B) Immunohistochemical staining for APE1/Ref-1 in bladder cancer. Positive cells are stained brown (black arrow). APE1/Ref-1 expression was clearly elevated in the tumor region, compared with non-tumor regions of bladder tissues. Mononuclear cells were infiltrated close to tumor regions (yellow arrows) (✕400). T, tumor cells.

References

    1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. - PubMed
    1. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011;43:1–11. - PMC - PubMed
    1. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–9. - PubMed
    1. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol. 2009;16:234–43. - PubMed
    1. Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR. Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol. 2007;127:946–53. - PubMed

Publication types

Substances